Condition: Type 2 Diabetes · Hypertension · Sponsor: THPharm Corp.
\[Primary Objective\] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102 (telmisartan 80 mg) compared to THP-00101 or THP-00102 monotherapy among subjects with type 2 diabetes mellitus accompanied by essential hypertension. \[Secondary Objective\] To comparatively evaluate secondary efficacy and safety in the THP-00101 monotherapy group, THP-00102 monotherapy group, THP-00101 and THP-00102 combination therapy group, and THP-00101 and THP-00103 (telmisartan 40 mg) combination therapy group among subjects with type 2 diabetes mellitus accompanied by essential hypertension.
This description comes directly from the study's public registry record.
Taehee Han, Dr. · 827086572278 · admin@thpharm.co.kr
Jaewoo Park · 827086572278 · jw.park@thpharm.co.kr
Always discuss trial participation with your own doctor first.
| The Catholic University of Korea, Yeouido ST. Mary's Hospital | Seoul, South Korea | Recruiting |
| Thammasat University Hospital | Pathum Thani, Changwat Pathum Thani, Thailand | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06647745